← Leaderboards
Zhongjie Fu
Boston Children'S Hospital
$3,205,944
Attributed
$4,212,662
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $969.8K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,212,662 · 2
By mechanism
R01$4,212,662 · 2
Top collaborators
- Lois Smith4 shared
Most similar at Boston Children'S Hospital
Same institution · by research overlap
- Lois Smith$17,647,467
- Elfar Adalsteinsson$8,294,641
- Patricia Ellen Grant$27,765,338
- John Nagi Kheir$4,394,281
- Alireza Shamshirsaz$245,324
Others in their field
Other Emerging Leaders on “Retinopathy Of Prematurity”
- John Peter Campbell · Oregon Health & Science University$5,273,396
- Ye Sun · Boston Children'S Hospital$4,181,435
- Christoph Hornik · Duke University$3,797,547
- Gopalan Gnanaguru · Massachusetts Eye And Ear Infirmary$3,220,224
- Md Imam Uddin · Vanderbilt University Medical Center$2,910,577
- Craig Gelfand · Advent Therapeutics, Inc.$2,774,847
Research focus
Retinopathy Of PrematurityRetinal DiseasesMitochondriaPostnatalPreventRetina Blood Vessel StructureIn UteroMetabolicNeovascularizationPathway InteractionsPremature BirthPremature InfantResponseRetinaBlood VesselsGrowthAreaCellsAttenuatedNeovascularOxygenOralAffectSerum
Grant awards (9)
Dietary control of angiogenesis in retinopathy models$490,455
R01 · FY2025 · EY
Serine control of retinal neovascularization in retinopathy$442,500
R01 · FY2025 · EY · contact PI
Dietary control of angiogenesis in retinopathy models$527,318
R01 · FY2024 · EY
Serine control of retinal neovascularization in retinopathy$442,500
R01 · FY2024 · EY · contact PI
Dietary control of angiogenesis in retinopathy models$519,169
R01 · FY2023 · EY
Serine control of retinal neovascularization in retinopathy$442,500
R01 · FY2023 · EY · contact PI
Dietary control of angiogenesis in retinopathy models$476,495
R01 · FY2022 · EY
Serine control of retinal neovascularization in retinopathy$429,225
R01 · FY2022 · EY · contact PI
Serine control of retinal neovascularization in retinopathy$442,500
R01 · FY2021 · EY · contact PI